ReviewEndocrine reviews2009
Unraveling insulin-like growth factor binding protein-3 actions in human disease.
Review in Endocrine reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 154 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
154 citing papers in PubMed, 2 syntheses or guidelines pooled it, 323 citations in OpenAlex.
- Pooled it
- Genome-wide association and functional studies identify a role for IGFBP3 in hip osteoarthritis.Annals of the rheumatic diseases · 2015Pooled it
- Persisting neuroendocrine abnormalities and their association with physical impairment 5 years after critical illness.Critical care (London, England) · 2021Trial
- A pharmacogenomic approach to the treatment of children with GH deficiency or Turner syndrome.European journal of endocrinology · 2013Trial
- Association between IGFBP-3 and longitudinal neuropsychiatric symptom trajectories in early Parkinson's disease: a longitudinal cohort study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Identification and Validation of the ESR1 Y537S Mutant-Enriched Enhancer and Its Downstream Target IGFBP3.Cancer research communications · 2026Article
- MAVS as a Key Regulator of Tumor Proliferation, Survival, the Tumor Microenvironment, and Immunity.Biomolecules · 2026Article
- Glycocalyx biomarkers as early predictors of endotheliopathy in pediatric and young adult hematopoietic stem cell transplantation patients.Frontiers in oncology · 2026Article
- Normative data for insulin-like growth factor-1 and insulin-like growth factor binding protein-3 and their determinants in healthy adult males from india: the INDIIGo study.Scientific reports · 2025Article
- Elevated IGFBP4 and Cognitive Impairment in a PTFE-Induced Mouse Model of Obstructive Sleep Apnea.International journal of molecular sciences · 2025Article
- Lower Initial Insulin-like Growth Factor-Binding Protein-3 Concentrations May Reflect Immune Suppression and Predict Increased Risk of Sepsis-Related Mortality.International journal of molecular sciences · 2025Article
- Humans with obesity exhibit impaired circulating total, but not free, IGF-1 response to acute endurance exercise.Physiological reports · 2025Article
- Study on molecular mechanism of intervertebral disc degeneration by single cell hdWGCNA combined with transcriptome sequencing.Non-coding RNA research · 2025Article
- Pan-cancer secreted proteome and skeletal muscle regulation: insight from a proteogenomic data-driven knowledge base.Functional & integrative genomics · 2025Review
- Role of IGFBP-3 in Human Diseases Relying on Different Cell Signaling Pathways.Advanced biomedical research · 2025Review
- The impact of insulin resistance and glycaemic control on insulin-like growth factor-1 in patients with type 2 diabetes: a cross-sectional study.Clinical diabetes and endocrinology · 2024Article
- Identification of a fibronectin-binding protein signature associated with idiopathic pulmonary fibrosis.Cells & development · 2024Article
- The role of IGFBP-3 in tumor development and progression: enlightenment for diagnosis and treatment.Medical oncology (Northwood, London, England) · 2024Review
- Article
- Review
94 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The IGF system plays critical roles in somatic growth in an endocrine fashion (somatomedin hypothesis) as well as proliferation and differentiation of normal and malignant cells in a paracrine/autocrine fashion. IGFBP-3 is known to modulate the actions of IGFs in circulation as well as the immediate extracellular environment. Interestingly, apart from the ability to inhibit or enhance IGF actions, IGFBP-3 also exhibits very clear, distinct biological effects independent of the IGF/IGF-I receptor axis. Over the past decade it has become widely appreciated that IGF/IGF-IR-independent actions of IGFBP-3 (antiproliferative and proapoptotic effects) contribute to improving the pathophysiology of a variety of human diseases, such as cancer, diabetes, and malnutrition. Recent studies have implicated interaction of IGFBP-3 with a variety of proteins or signaling cascades critical to cell cycle control and apoptosis; however, the actual mechanism of IGFBP-3 action is still unclear. This review reinforces the concept in support of the IGF/IGF-IR axis-independent actions of IGFBP-3 and delineates potential underlying mechanisms involved and subsequent biological significance, focusing in particular on functional binding partners and the clinical significance of IGFBP-3 in the assessment of cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.